Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients

Phase 1positiveSKY-0515Positive

AI Analysis

Summary

Skyhawk Therapeutics announced final fifteen-month results from its Phase 1/2 trial of SKY-0515 in Huntington's Disease patients, showing a +1.59-point difference in cUHDRS change from baseline at the primary timepoint. This represents the final analysis from the ongoing clinical program.

Clinical Trial Data

Phase

Phase 1/2

Primary Endpoint

Met

Outcome Details

At Month 15 primary timepoint, SKY-0515-treated patients showed a +1.59-point difference in cUHDRS change from baseline

Importance:5/10

Sentiment:

0.65

Phase 1/2 dataHuntington's DiseasecUHDRS endpointfinal analysis

Read the original article

Published by PR Newswire Pharma on September 15, 2026 4:20 PM

Read Original